A Study to Assess an Automated Laser Device for Direct Selective Laser Trabeculoplasty (GLAUrious)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03750201|
Recruitment Status : Recruiting
First Posted : November 21, 2018
Last Update Posted : September 5, 2021
Glaucoma is an eye disease that results in damage to the optic nerve that progresses over time. One of the main risk factors in glaucoma is an increase in intraocular pressure, caused by a build-up of fluid in the eye. Glaucoma can result in blindness if left untreated and as such it is extremely important to diagnose and treat the condition.
Selective Laser Trabeculoplasty (SLT) is a laser treatment that facilitates the outflow of fluid from inside the eye. This has the potential of reducing the intraocular pressure within the eye (the main way in which this disease is treated since there is no cure) and may assist in helping to control the progression of this disease.
SLT (standard treatment) is a technique routinely carried out by glaucoma specialists. It is conducted using a special type of lens (goniolens) that gently sits on the front surface of the eye. The procedure takes approximately 5 minutes in duration.
This new treatment, Direct Selective Laser Trabeculoplasty (DSLT) is performed directly, without there being any need to use a goniolens which sits on the eye, and it is a shorter and simpler technique to conduct when compared to the standard SLT technique.
The purpose of this study is to assess the hypothesis that the treatment by new automated device for DSLT is not worse in comparison with the standard SLT and determine that it is effective in reducing intraocular pressure.
|Condition or disease||Intervention/treatment||Phase|
|Open Angle Glaucoma Ocular Hypertension||Device: Direct Selective Trabeculoplasty Device: Selective Trabeculoplasty||Not Applicable|
Glaucoma can result in blindness if left untreated and as such it is extremely important to diagnose and treat the condition.
Usually doctors treat the first symptoms of glaucoma or ocular hypertension by prescribing eye drops. Unfortunately, there can be side effects associated with the use of these eye drops and there are reports of non-compliance due to difficulties in inserting these drops, all of which can impact on how effective this treatment regimen is.
The purpose of this study is to assess how well the new automated DSLT device for laser treatment of glaucoma or ocular hypertension works in comparison with the standard SLT and determine that it is as effective in reducing intraocular pressure.
DSLT or SLT will be performed in the study eye according to the randomization assignment. Eligible patients who sign the informed consent will be enrolled at each of the study sites, and undergo a washout (in the case of being medicated). After washout there will be a baseline visit, where continued eligibility is confirmed. Following confirmation of continued eligibility, 50% of patients being randomized to each treatment group. Randomization will be to a pre-determined randomization list.
The un-masked investigator(s) will open the envelope corresponding to the subject ID and administer the treatment as indicated by the randomization envelope. The masked ophthalmologist(s), who will perform the follow up, will be masked as to the nature of the treatment the patient underwent.
Only one eye per participant will be included in the study and they will be treated using either DSLT or SLT as per the randomized treatment allocation.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||192 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Single (Outcomes Assessor)|
|Masking Description:||Intra-ocular pressure (IOP) measurements by masked investigator or masked technique (masked reading).|
|Official Title:||Direct Selective Laser Trabeculoplasty (DSLT) In Open Angle Glaucoma (POAG): A Randomized Controlled Trial|
|Actual Study Start Date :||October 19, 2018|
|Estimated Primary Completion Date :||April 2022|
|Estimated Study Completion Date :||November 2022|
Experimental: Direct Selective Trabeculoplasty
Treatment by the investigational device.
Device: Direct Selective Trabeculoplasty
Laser surgery by automated direct automated SLT device to lower intraocular pressure
Active Comparator: Selective Trabeculoplasty
Treatment by the comparator device.
Device: Selective Trabeculoplasty
Laser surgery by standard SLT device to lower intraocular pressure
- The difference between the two treatment groups between the mean baseline IOP and the mean IOP after the treatment [ Time Frame: 6 months ]The mean baseline IOP (washed out for medicated patients) will be compared to the mean (washed out for medicated patients) IOP after the treatment
- Number of medications as compare to screening visit [ Time Frame: 6 months ]Number of medications at 6 months as compared to screening/Visit 1 (before treatment) and compared between groups.
- Proportion of subjects with at least 20% reduction in IOP from baseline [ Time Frame: 6 months ]Proportion of subjects with at least 20% reduction in IOP at 6 months compared to baseline without surgical intervention
- Incidence of adverse events [ Time Frame: 12 months ]Rates of Ocular Adverse events (AEs) in each treatment group at or prior to the 12 months visit
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03750201
|Contact: Yoram Solberg, MD PhDfirstname.lastname@example.org|
|Soroka Medical Center||Recruiting|
|Be'er Sheva, Israel|
|Contact: Mor Portnikov MorPo@clalit.org.il|
|Principal Investigator: Assaff Kratz, Dr|
|Rambam Medical Center||Recruiting|
|Contact: Meital Abecassis email@example.com|
|Principal Investigator: Eytan Blumenthal, Prof|
|Wolfson Medical Center||Recruiting|
|Contact: Elizabeth Drozdov Elizabethd@wmc.gov.il|
|Principal Investigator: Maya Kalev - Lindoy, Dr|
|Shaare Zedek Medical Center||Recruiting|
|Contact: Hila Givoni firstname.lastname@example.org|
|Principal Investigator: Zohar Bracha, Dr|
|Rabin Medical Center||Recruiting|
|Contact: Vivi Dagan 03-9377199 email@example.com|
|Principal Investigator: Noa Geffen, Prof|
|Universita degli Studi di Genova||Recruiting|
|Contact: Maura Cavo +3901035338290 firstname.lastname@example.org|
|Contact: Luca Bagnasco, PhD|
|Principal Investigator: Carlo E Traverso, MD|
|Queens University Belfast||Recruiting|
|Belfast, United Kingdom|
|Contact: Lucia Dalton 07768 858583 L.Dalton@qub.ac.uk|
|Principal Investigator: Augusto Azuara-Blanco, PhD,FRCOphth|
|Moorfields Eye Hospital||Recruiting|
|London, United Kingdom, EC1V 2PD|
|Contact: Reem Deib 0207 566 2821 email@example.com|
|Principal Investigator: Gus Gazzard, Prof.|
|Principal Investigator:||Nathan Congdon, MD, MPH||Queens University Belfast|